Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has filed for a Phase III clinical study of its Claudin18.2-targeted antibody drug conjugate (ADC) SHR-A1904 on Clinicaltrials.gov. The study aims to enroll 524 patients with second-line recurrent or metastatic gastric cancer and is anticipated to reach a preliminary conclusion by the beginning of September 2027.
SHR-A1904, which has previously received clearance for studies in both the United States and China, is currently under investigation for the treatment of advanced pancreatic cancer and other advanced solid tumors as a monotherapy. Additionally, it is being evaluated in combination with Hengrui’s adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), for the treatment of advanced solid tumors.
This Phase III study filing underscores Jiangsu Hengrui Medicine’s commitment to advancing targeted therapies for gastric cancer and highlights the company’s efforts in expanding the therapeutic potential of SHR-A1904 across a range of cancer indications.- Flcube.com
